Cite

HARVARD Citation

    Rebhan, K. et al. (2022). Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Current opinion in urology. 32 (4), pp. 358-363. [Online]. 
  
Back to record